Driving Access Through Reliable Science
Biosimilars are biologic medicines that match existing reference products in terms of quality, safety, and efficacy. They offer healthcare systems a way to manage costs while maintaining therapeutic standards – a critical factor in ensuring long-term sustainability.
Fresenius Kabi’s approach to biosimilars is rooted in scientific rigor and operational excellence. Our vertically integrated model – from development and manufacturing to distribution – ensures reliability and resilience across the supply chain.
A Year of Milestones for Our Biosimilars Portfolio
2025 has been an unprecedented year for our biosimilars portfolio, achieving two major approvals and three launches, expanding our reach to millions more patients across autoimmune diseases, bone disorders, and oncology. We also expanded our global footprint and reinforced our commitment to therapeutic access.
These milestones reflect the dedication of our teams and the trust placed in Fresenius Kabi by healthcare professionals and partners worldwide.
Join the Global Conversation on Biosimilars
Global Biosimilars Week is an opportunity to raise awareness of the value biosimilars bring to healthcare systems and patients worldwide.
We support the IGBA-led initiative and encourage stakeholders including healthcare professionals, policymakers, and patient advocates to explore educational resources and insights about biosimilars.
Learn more about Global Biosimilars Week 2025 on the official website.
